!Important update: There’s a new process to prescribe HEMANGEOL.Click here
HEMANGEOL (propranolol hydrochloride) oral solution 4.28 mg/mL
For Healthcare Professionals

Discover
HEMANGEOL.

An effective treatment with an established safety profile for an infantile hemangioma (IH)

HEMANGEOL® (propranolol hydrochloride) oral solution is indicated for the treatment of proliferating infantile hemangiomas that require systemic therapy.

Read More on Infantile Hemangioma

Please see important safety information below.

Prescribing HEMANGEOL

Getting Started Is Simple

HEMANGEOL is dispensed through our dedicated specialty pharmacy
Anovo Rx, with Eton Cares support for benefits investigation, prior authorizations, and affordability for eligible patients.

Anovo Specialty Pharmacy logoHow to Prescribe HEMANGEOL

Proven Efficacy

  • 6 out of 10 babies on HEMANGEOL had their infantile hemangioma lesion “completely or nearly completely resolved” by 6 months of therapy versus only 4% of babies who received no treatment (n=101).1*
  • Nearly 9 out of 10 of the babies treated with HEMANGEOL showed improvement by 5 weeks, compared with 5% of babies who received no treatment (n=55).2**
Read More on Efficacy

BID Dosing

  • 3.4 mg/kg divided into 2 daily doses for 6 months was identified as the optimal maintenance dose in a double-blind clinical trial.1
  • Dosing Chart available below for determining the appropriate dose for your patients.
Read More on Dosing

Safety Profile

  • Fewer than 2% of patients discontinued treatment due to adverse reactions.1
  • The most frequently reported adverse reactions (>10%) in infants treated with HEMANGEOL were sleep disorders, aggravated respiratory tract infections such as bronchitis and bronchiolitis associated with cough and fever, diarrhea, and vomiting.1
Read More on Safety

*Based on independent-investigator assessment of telangiectasis, color, textural change, and distortion of anatomical landmarks or skin contours compared to baseline. (n=55).2

**Of patients on HEMANGEOL 3.4 mg/kg/day for 6 months who were considered successes, 10% required retreatment for recurrence of hemangiomas.

HEMANGEOL bottle

What is HEMANGEOL?

HEMANGEOL is a prescription medicine used to treat proliferating infantile hemangioma that requires systemic therapy. To get started with HEMANGEOL, follow the get started button.

About HEMANGEOL
Dosing

HEMANGEOL Dosing Chart

Our Dosing Chart provides weight-based dosing (kg) by Week 1, Week 2, and Week 3 (maintenance dose). Download the chart below for your records.

Dosing & Administration Download HEMANGEOL Dosing Chart
HEMANGEOL Dosing Chart preview
Healthcare Provider Resources

Providing The Best for Your Patients

We provide published data and patient education materials for healthcare providers to use with patients and their caregivers. If you have questions about these resources, please contact us.

Resources
Parents holding their infant while speaking with a healthcare provider

References

  1. HEMANGEOL [Prescribing Information]. Eton Pharmaceuticals, Inc.
  2. Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J, et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med. 2015;372:735. https://www.nejm.org/doi/full/10.1056/NEJMoa1404710
Important Safety Information

INDICATION: HEMANGEOL oral solution is a beta-adrenergic blocker indicated for the treatment of proliferating infantile hemangioma requiring systemic therapy.

CONTRAINDICATIONS: HEMANGEOL is contraindicated in: premature infants with corrected age <5 weeks; infants weighing <2 kg; hypersensitivity to propranolol or excipients; asthma or history of bronchospasm; bradycardia (<80 bpm), greater than first-degree heart block, or decompensated heart failure; blood pressure <50/30 mmHg; pheochromocytoma.